Please note that this event has been cancelled. We will update you with any future reschedule date.
Professor of Neurosurgery, Harvard Medical School Brigham and Women’s Hospital, Neuroscience Center Dana-Faber Cancer Institute, Center for Neuro-Oncology Boston, Massachusetts, USA
A “first-in-human” phase 1 trial of intralesional injection of CAN-3110, an immunotherapeutic oncolytic based on herpes simplex virus 1 (HSV1), was conducted in 41 subjects with recurrent high-grade glioma (rHGG). The impact of CAN-3110 on the tumor immune microenvironment was assessed using immunohistochemistry, multiplexed immunofluorescence, TCR-beta DNA sequencing, and bulk RNA sequencing of paired pre- and post-treatment samples. These analyses were combined with patient features to identify potential biomarkers of therapy response in rHGG.
In IDH wild type recurrent glioblastoma (IDHwt rGBM) patients, post-treatment survival times were positively associated with positive pre-treatment HSV1 serology after controlling for additional covariates such as tumor volume, age, gender, CAN-3110 dose, etc. (HR = 0.16, p < 0.001, n = 32, CoxPH). Positive HSV1 serology was also significantly associated with clearance of CAN-3110 from injected tumors. Interestingly, increased intratumoral CD8 and CD4 T cell numbers following treatment were positively associated with prolonged survival in HSV1 seropositive patients (p = 0.017 and 0.026, respectively), but
not when analyses were conducted including HSV1 seronegative patients. Likewise, post-treatment immune expression signatures (such as for antitumor cytokines, T cell traffic, etc.) were more strongly associated with prolonged survival for HSV1 seropositive patients than for seronegative patients, and most assessed immune signatures only became associated with survival after CAN-3110 treatment. Extended survival was also associated with increased TCR-beta diversity following therapy in both the tumor and in PBMCs.
Combined with a lack of observed dose-limiting toxicities and a median post-treatment survival of 14.2 months (95% CI: 9.5-15.7) in IDHwt rGBM patients with positive HSV1 serology, these data provide evidence that intralesional CAN-3110 treatment is capable of generating immune activation in a traditionally immunologically cold tumor in a way that influences survival time—particularly when patients have had prior exposure to HSV1. (clinicaltrials.gov NCT03152318)
CHL – Centre
Room Amphitheatre
4, rue Nicolas Ernest Barblé
L-1210 Luxembourg (Belair)
LECTURE: 11:00am – 12:00pm
12:30pm – 13:30pm
DoCR
Room McClintock (2nd floor)
6A, rue Nicolas-Ernest Barblé
L-1210 Luxembourg
Light lunch provided
Supported by:
Read more about the “Data Protection Notice: processing of personal data in the scope of events’ management”.